Active clinical trials for "Asthma"

The main objectives of the study are to study the different T cell subtypes (Th1, Th2, Th17 and Treg) in the lower airways of healthy subjects and clinically different asthma patients, based on a non-invasive procedure of sputum induction. Patients will be different in function of age, in relation to the trigger (eg aspirin, without or with association with polyposis), without or with underlying atopic sensitization or different in the type of underlying inflammation (eosinophilic vs neutrophilic). This T cell pattern will become the basis of molecular phenotyping in the patients. to study the usefulness of asthma molecular phenotyping (by following the balance between the inflammatory markers on the one hand and the regulatory markers on the other hand) in asthma guidance (longitudinally). The final goal of this project is then to develop a sputum non-invasive biomarker array that can be used to distinguish the different inflammatory asthma phenotypes and that can predict steroid resistance and/or sensitivity to other anti-inflammatory medication, using a non-invasive technique that can be used also at young age and repetitively.

The purpose of this study is to identify community resources and challenges in improving the health of community members with asthma. The primary goal of this project is to use Community-Based Participatory Research methodology to develop interventions aimed at improving asthma management in high-risk African American asthmatics. This "ground-up" longterm approach has never been tested before in asthmatics. The primary goal of this study will be accomplished with four specific aims: Aim 1. Conduct focus groups to identify barriers to asthma management in the target population. Aim 2. Use a community advisory board (CAB) consisting of participants selected from the various focus groups to gather information about solutions for the above barriers. Aim 3. Use the information from the CAB to develop an intervention to improve asthma self management behaviors in the target population. Aim 4. Refine the developed intervention based on feedback from focus groups conducted in Aim 1.

This study will help to find out if having a certain genetic makeup influences how a person with asthma responds to salmeterol, one of the two drugs in Advair(R).

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice

The prevalence of obesity and asthma has increased in recent decades. We investigated the relationship between body mass index (BMI) and lung function, and also tried to determine if asthma prevalence differs between obese and non-obese children. We propose this cross-sectional, retrospective analysis to figure out whether the BMI is associated with elevated prevalence of asthma, and how their lung function changes in different BMI groups.

This study will evaluate the link between blood group antigens and asthma exacerbations.

Childhood Asthma and Schooling: The Truth Unveiled.

A prospective study led amongst pulmonologists. Patients asthma control level will be evaluated based on GINA guideline criteria. HRQoL measured by Visual analogue scale. Clinical practice: non controlled patients therapy assessed.

The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.

This is a retrospective observational study utilising anonymised individual patient clinical and prescribing information routinely collected by UK General Practitioners (GPs). This information will be observed for two years, one year pre and one year post- "Index Prescription Date" (IPD). The IPD is the date when a patient was first switched to any option of the step-3 asthma treatment regimen. The one year before the IPD is the baseline period and will be reviewed for risk factors and confounding factors. The one year after the IPD is the outcome period and will be observed to see the outcomes of the new treatment.